Free Trial
→ Important SpaceX PREDICTION (From Banyan Hill Publishing) (Ad)tc pixel Free BIOG Stock Alerts

The Biotech Growth Trust (BIOG) Competitors

The Biotech Growth Trust logo
GBX 1,262 +22.00 (+1.77%)
As of 06/11/2026 12:00 PM Eastern
Compare

BIOG vs. GROW, TRY, JPE, SOI, and BBGI

Should you buy The Biotech Growth Trust stock or one of its competitors? MarketBeat compares The Biotech Growth Trust with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with The Biotech Growth Trust include Molten Ventures (GROW), TR Property Investment Trust (TRY), JPMorgan Elect plc ­- Managed Growth (JPE), Schroder Oriental Income (SOI), and BBGI Global Infrastructure (BBGI). These companies are all part of the "asset management" industry.

How does The Biotech Growth Trust compare to Molten Ventures?

Molten Ventures (LON:GROW) and The Biotech Growth Trust (LON:BIOG) are both small-cap financial services companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Molten Ventures has a net margin of 193.06% compared to The Biotech Growth Trust's net margin of 96.47%. The Biotech Growth Trust's return on equity of 48.26% beat Molten Ventures' return on equity.

Company Net Margins Return on Equity Return on Assets
Molten Ventures193.06% 8.81% -3.46%
The Biotech Growth Trust 96.47%48.26%12.39%

Molten Ventures has a beta of 1.9414055, meaning that its stock price is 94% more volatile than the broader market. Comparatively, The Biotech Growth Trust has a beta of 0.59646654, meaning that its stock price is 40% less volatile than the broader market.

In the previous week, Molten Ventures had 4 more articles in the media than The Biotech Growth Trust. MarketBeat recorded 5 mentions for Molten Ventures and 1 mentions for The Biotech Growth Trust. The Biotech Growth Trust's average media sentiment score of 1.42 beat Molten Ventures' score of 1.15 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Molten Ventures
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
The Biotech Growth Trust
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

41.3% of Molten Ventures shares are held by institutional investors. Comparatively, 10.5% of The Biotech Growth Trust shares are held by institutional investors. 1.6% of Molten Ventures shares are held by insiders. Comparatively, 2.9% of The Biotech Growth Trust shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

The Biotech Growth Trust has lower revenue, but higher earnings than Molten Ventures. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Molten Ventures, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molten Ventures£125.60M8.53-£33.58M£61.6010.10
The Biotech Growth Trust-£17.73M-13.81£83.83M£558.002.26

Molten Ventures currently has a consensus price target of GBX 599.67, suggesting a potential downside of 3.59%. Given Molten Ventures' stronger consensus rating and higher possible upside, equities analysts clearly believe Molten Ventures is more favorable than The Biotech Growth Trust.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Molten Ventures
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
The Biotech Growth Trust
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Molten Ventures beats The Biotech Growth Trust on 10 of the 16 factors compared between the two stocks.

How does The Biotech Growth Trust compare to TR Property Investment Trust?

The Biotech Growth Trust (LON:BIOG) and TR Property Investment Trust (LON:TRY) are both small-cap financial services companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

The Biotech Growth Trust has a beta of 0.59646654, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, TR Property Investment Trust has a beta of 1.4909836, suggesting that its stock price is 49% more volatile than the broader market.

The Biotech Growth Trust has a net margin of 96.47% compared to TR Property Investment Trust's net margin of 79.93%. The Biotech Growth Trust's return on equity of 48.26% beat TR Property Investment Trust's return on equity.

Company Net Margins Return on Equity Return on Assets
The Biotech Growth Trust96.47% 48.26% 12.39%
TR Property Investment Trust 79.93%6.52%-24.58%

In the previous week, TR Property Investment Trust had 6 more articles in the media than The Biotech Growth Trust. MarketBeat recorded 7 mentions for TR Property Investment Trust and 1 mentions for The Biotech Growth Trust. The Biotech Growth Trust's average media sentiment score of 1.42 beat TR Property Investment Trust's score of 1.13 indicating that The Biotech Growth Trust is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
The Biotech Growth Trust
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
TR Property Investment Trust
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

TR Property Investment Trust has lower revenue, but higher earnings than The Biotech Growth Trust. TR Property Investment Trust is trading at a lower price-to-earnings ratio than The Biotech Growth Trust, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Biotech Growth Trust-£17.73M-13.81£83.83M£558.002.26
TR Property Investment Trust-£27.26M-35.74£284.71M-£11.35N/A

10.5% of The Biotech Growth Trust shares are held by institutional investors. Comparatively, 12.8% of TR Property Investment Trust shares are held by institutional investors. 2.9% of The Biotech Growth Trust shares are held by company insiders. Comparatively, 0.2% of TR Property Investment Trust shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

The Biotech Growth Trust beats TR Property Investment Trust on 9 of the 13 factors compared between the two stocks.

How does The Biotech Growth Trust compare to JPMorgan Elect plc ­- Managed Growth?

The Biotech Growth Trust (LON:BIOG) and JPMorgan Elect plc ­- Managed Growth (LON:JPE) are both small-cap asset management industry companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

The Biotech Growth Trust has higher earnings, but lower revenue than JPMorgan Elect plc ­- Managed Growth. JPMorgan Elect plc ­- Managed Growth is trading at a lower price-to-earnings ratio than The Biotech Growth Trust, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Biotech Growth Trust-£17.73M-13.81£83.83M£558.002.26
JPMorgan Elect plc ­- Managed Growth£104.78M0.00N/A£0.75N/A

In the previous week, The Biotech Growth Trust had 1 more articles in the media than JPMorgan Elect plc ­- Managed Growth. MarketBeat recorded 1 mentions for The Biotech Growth Trust and 0 mentions for JPMorgan Elect plc ­- Managed Growth. The Biotech Growth Trust's average media sentiment score of 1.42 beat JPMorgan Elect plc ­- Managed Growth's score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the media.

Company Overall Sentiment
The Biotech Growth Trust Positive
JPMorgan Elect plc ­- Managed Growth Neutral

The Biotech Growth Trust has a net margin of 96.47% compared to JPMorgan Elect plc ­- Managed Growth's net margin of 0.00%. The Biotech Growth Trust's return on equity of 48.26% beat JPMorgan Elect plc ­- Managed Growth's return on equity.

Company Net Margins Return on Equity Return on Assets
The Biotech Growth Trust96.47% 48.26% 12.39%
JPMorgan Elect plc ­- Managed Growth N/A N/A N/A

10.5% of The Biotech Growth Trust shares are owned by institutional investors. 2.9% of The Biotech Growth Trust shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

The Biotech Growth Trust beats JPMorgan Elect plc ­- Managed Growth on 8 of the 10 factors compared between the two stocks.

How does The Biotech Growth Trust compare to Schroder Oriental Income?

Schroder Oriental Income (LON:SOI) and The Biotech Growth Trust (LON:BIOG) are both small-cap asset management industry companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

In the previous week, The Biotech Growth Trust had 1 more articles in the media than Schroder Oriental Income. MarketBeat recorded 1 mentions for The Biotech Growth Trust and 0 mentions for Schroder Oriental Income. The Biotech Growth Trust's average media sentiment score of 1.42 beat Schroder Oriental Income's score of 0.20 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.

Company Overall Sentiment
Schroder Oriental Income Neutral
The Biotech Growth Trust Positive

Schroder Oriental Income has a beta of 0.645, suggesting that its stock price is 36% less volatile than the broader market. Comparatively, The Biotech Growth Trust has a beta of 0.59646654, suggesting that its stock price is 40% less volatile than the broader market.

The Biotech Growth Trust has a net margin of 96.47% compared to Schroder Oriental Income's net margin of 94.62%. The Biotech Growth Trust's return on equity of 48.26% beat Schroder Oriental Income's return on equity.

Company Net Margins Return on Equity Return on Assets
Schroder Oriental Income94.62% 39.20% -2.12%
The Biotech Growth Trust 96.47%48.26%12.39%

Schroder Oriental Income has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Schroder Oriental Income, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schroder Oriental Income£334.18M2.87£106.18M£144.692.97
The Biotech Growth Trust-£17.73M-13.81£83.83M£558.002.26

9.7% of Schroder Oriental Income shares are owned by institutional investors. Comparatively, 10.5% of The Biotech Growth Trust shares are owned by institutional investors. 0.1% of Schroder Oriental Income shares are owned by insiders. Comparatively, 2.9% of The Biotech Growth Trust shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

The Biotech Growth Trust beats Schroder Oriental Income on 8 of the 13 factors compared between the two stocks.

How does The Biotech Growth Trust compare to BBGI Global Infrastructure?

BBGI Global Infrastructure (LON:BBGI) and The Biotech Growth Trust (LON:BIOG) are both small-cap financial services companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

BBGI Global Infrastructure has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, The Biotech Growth Trust has a beta of 0.59646654, suggesting that its share price is 40% less volatile than the broader market.

The Biotech Growth Trust has a net margin of 96.47% compared to BBGI Global Infrastructure's net margin of 61.84%. The Biotech Growth Trust's return on equity of 48.26% beat BBGI Global Infrastructure's return on equity.

Company Net Margins Return on Equity Return on Assets
BBGI Global Infrastructure61.84% 2.52% 3.32%
The Biotech Growth Trust 96.47%48.26%12.39%

58.9% of BBGI Global Infrastructure shares are held by institutional investors. Comparatively, 10.5% of The Biotech Growth Trust shares are held by institutional investors. 0.5% of BBGI Global Infrastructure shares are held by insiders. Comparatively, 2.9% of The Biotech Growth Trust shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

The Biotech Growth Trust has lower revenue, but higher earnings than BBGI Global Infrastructure. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than BBGI Global Infrastructure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BBGI Global Infrastructure£67.98M14.48£54.89M£7.7217.93
The Biotech Growth Trust-£17.73M-13.81£83.83M£558.002.26

In the previous week, The Biotech Growth Trust had 1 more articles in the media than BBGI Global Infrastructure. MarketBeat recorded 1 mentions for The Biotech Growth Trust and 0 mentions for BBGI Global Infrastructure. The Biotech Growth Trust's average media sentiment score of 1.42 beat BBGI Global Infrastructure's score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.

Company Overall Sentiment
BBGI Global Infrastructure Neutral
The Biotech Growth Trust Positive

Summary

The Biotech Growth Trust beats BBGI Global Infrastructure on 9 of the 13 factors compared between the two stocks.

Get The Biotech Growth Trust News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIOG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIOG vs. The Competition

Export
MetricThe Biotech Growth TrustAsset Management IndustryFinancial SectorLON Exchange
Market Cap£244.83M£2.42B£5.74B£2.73B
Dividend YieldN/A6.03%5.29%6.13%
P/E Ratio2.2625.7116.33366.48
Price / Sales-13.812,038.131,092.7886,600.07
Price / Cash87.7460.3389.1227.87
Price / Book1.171.366.517.62
Net Income£83.83M£265.36M£1.13B£5.89B
7 Day Performance0.64%-0.20%0.64%-0.99%
1 Month Performance-6.24%-0.14%1.17%1.09%
1 Year Performance64.75%9.43%18.77%72.42%

The Biotech Growth Trust Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIOG
The Biotech Growth Trust
N/AGBX 1,262
+1.8%		N/A+63.0%£244.83M-£17.73M2.26N/A
GROW
Molten Ventures
1.4778 of 5 stars		GBX 589
+1.5%		GBX 599.67
+1.8%		+99.0%£1.01B£125.60M9.5620
TRY
TR Property Investment Trust
N/AGBX 317
-0.2%		N/A-7.8%£1.01B-£27.26MN/A26
JPE
JPMorgan Elect plc ­- Managed Growth
N/AN/AN/AN/A£1.00B£104.78M1,250.00N/A
SOI
Schroder Oriental Income
N/AGBX 440
flat		N/A+51.2%£986.61M£97.72M10.86180

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BIOG) was last updated on 6/12/2026 by MarketBeat.com Staff.
From Our Partners
Is your wealth prepared for “America’s Most Dangerous Man”? (Read before June 16)
60-year Wall Street veteran Marc Chaikin is issuing an urgent warning about the billionaire behind an AI lab t...
Chaikin Analytics | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The chokepoint supplier behind SpaceX's $1.75 trillion empire
When Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...
Behind the Markets | Sponsoredtc pixel
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...
InvestPub | Sponsoredtc pixel
Live demo of Elon Musk’s AI agent
Jeff Brown picked Nvidia in 2016 - it's up 25,155%. He recommended Bitcoin at $240 - it's up 31,219%. Now he's...
Brownstone Research | Sponsoredtc pixel
OpenAI is preparing to go public
OpenAI - the company behind ChatGPT - has begun filing confidential paperwork for what could be the largest IP...
InvestorPlace | Sponsoredtc pixel
Trump’s secret China deal
Trump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...
Porter & Company | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel